Fergal J O'Donoghue1,2,3, Jean-Christian Borel3,4, Yves Dauvilliers5, Patrick Levy3,4, Renaud Tamisier3,4, Jean-Louis Pépin3,4. 1. Institute for Breathing and Sleep, Austin Health, Melbourne, Victoria, Australia. 2. The University of Melbourne, Melbourne, Victoria, Australia. 3. EFCR and Sleep Laboratory, Grenoble Alpes University Hospital, Grenoble, France. 4. HP2 Laboratory, INSERM U1042, Grenoble Alpes University, Grenoble, France. 5. Sleep Unit, Department of Neurology, INSERM U1061, Gui-de Chauliac Hospital, Montpellier, France.
Abstract
BACKGROUND AND OBJECTIVE: The benefits of domiciliary non-invasive ventilation (NIV) in myotonic dystrophy type 1 (DM1) are unclear. We sought to determine the effects of elective discontinuation of ventilatory support for 1 month in DM1 patients receiving NIV for chronic hypercapnic respiratory failure. METHODS: At baseline, 12 patients underwent polysomnography, and assessment of subjective (Epworth Sleepiness Scale) and objective (Oxford Sleep Resistance Test) sleepiness, fatigue (Fatigue Severity Scale), respiratory function including muscle strength, arterial blood gas (ABG), hypercapnic ventilatory response (HCVR), Blood Pressure, peripheral arterial tonometry (PAT) and pulse wave velocity (PWV). They also completed the SF36. Testing was repeated (Visit 2) 1 month after elective cessation of NIV and again (Visit 3) 1 month after NIV reintroduction. RESULTS: No changes were seen in SF36, sleepiness or fatigue, respiratory function, muscle strength nor HCVR. Likewise, there were no changes in Blood Pressure, PAT or PWV. Mean nocturnal SpO2 deteriorated off NIV and improved on resumption (mean ± SD = 95.02 ± 1.90%, 92.23 ± 3.61% and 95.08 ± 2.28%, P = 0.006 change Visit 1 to Visit 2, 0.009 Visit 2 to Visit 3). Daytime PaCO2 (arterial partial pressure of carbon dioxide) was 43.13 ± 4.20 mm Hg, 46.28 ± 2.25 mm Hg and 43.87 ± 2.85 mm Hg, P = 0.056 and 0.017 over the same intervals. CONCLUSION: DM1 patients derive little benefit in symptoms or quality of life from NIV. Nocturnal and diurnal ventilatory functions deteriorate slightly off NIV for 1 month, but this does not appear to be due to changes in HCVR or respiratory function. HCVR changes may be of primary CNS origin given stability on or off NIV.
BACKGROUND AND OBJECTIVE: The benefits of domiciliary non-invasive ventilation (NIV) in myotonic dystrophy type 1 (DM1) are unclear. We sought to determine the effects of elective discontinuation of ventilatory support for 1 month in DM1 patients receiving NIV for chronic hypercapnic respiratory failure. METHODS: At baseline, 12 patients underwent polysomnography, and assessment of subjective (Epworth Sleepiness Scale) and objective (Oxford Sleep Resistance Test) sleepiness, fatigue (Fatigue Severity Scale), respiratory function including muscle strength, arterial blood gas (ABG), hypercapnic ventilatory response (HCVR), Blood Pressure, peripheral arterial tonometry (PAT) and pulse wave velocity (PWV). They also completed the SF36. Testing was repeated (Visit 2) 1 month after elective cessation of NIV and again (Visit 3) 1 month after NIV reintroduction. RESULTS: No changes were seen in SF36, sleepiness or fatigue, respiratory function, muscle strength nor HCVR. Likewise, there were no changes in Blood Pressure, PAT or PWV. Mean nocturnal SpO2 deteriorated off NIV and improved on resumption (mean ± SD = 95.02 ± 1.90%, 92.23 ± 3.61% and 95.08 ± 2.28%, P = 0.006 change Visit 1 to Visit 2, 0.009 Visit 2 to Visit 3). Daytime PaCO2 (arterial partial pressure of carbon dioxide) was 43.13 ± 4.20 mm Hg, 46.28 ± 2.25 mm Hg and 43.87 ± 2.85 mm Hg, P = 0.056 and 0.017 over the same intervals. CONCLUSION: DM1 patients derive little benefit in symptoms or quality of life from NIV. Nocturnal and diurnal ventilatory functions deteriorate slightly off NIV for 1 month, but this does not appear to be due to changes in HCVR or respiratory function. HCVR changes may be of primary CNS origin given stability on or off NIV.
Authors: Bettine A H Vosse; Charlotte Seijger; Nicolle Cobben; Baziel van Engelen; Sander M J van Kuijk; Catharina Faber; Peter Wijkstra Journal: Respiration Date: 2021-05-07 Impact factor: 3.580
Authors: Anna Christina Meyer; Jens Spiesshoefer; Nina Christina Siebers; Anna Heidbreder; Christian Thiedemann; Hartmut Schneider; Andrew T Braun; Winfried Randerath; Peter Young; Michael Dreher; Matthias Boentert Journal: Sleep Breath Date: 2020-12-02 Impact factor: 2.816
Authors: Carola R Ferrari Aggradi; Elisa Falcier; Andrea Lizio; Alice Pirola; Jacopo Casiraghi; Alice Zanolini; Elena Carraro; Luca Mauro; Fabrizio Rao; Elisabetta Roma; Antonino Iannello; Elisa De Mattia; Andrea Barp; Sara Lupone; Valentina Gatti; Cristina Italiano; Valeria A Sansone Journal: Can Respir J Date: 2022-06-18 Impact factor: 2.130
Authors: Jacob N Miller; Ellen van der Plas; Mark Hamilton; Timothy R Koscik; Laurie Gutmann; Sarah A Cumming; Darren G Monckton; Peggy C Nopoulos Journal: Neurol Genet Date: 2020-08-12